MedTrace Logo

Fluticasone Nasal Spray Patient Preference Study

NCT00398476 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 127

Last updated 2018-03-01

Study results available
· View outcomes & findings →

Summary

The objectives of this study are to evaluate and compare patient preference for FF (Fluticasone Furoate) and FP (Fluticasone Propionate Aqueous)nasal sprays in the treatment of allergic rhinitis following single-dose administration.

Conditions

  • Rhinitis, Allergic, Perennial

Interventions

DRUG

fluticasone propionate (FP)

200 micrograms (mcg); an aqueous suspension of microfine FP

DRUG

fluticasone furoate (FF)

110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-01
Primary Completion
2006-12-04
Completion
2006-12-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00398476 on ClinicalTrials.gov